Announcement on the Initial Grant of Restricted Shares to Participants of the 2026 Restricted Share Incentive Plan

Stock Code: 301096 Stock Abbreviation: Baicheng Medical Announcement No.: 2026-032

Hangzhou Baicheng Medical Technology Co., Ltd.

Announcement on the Initial Grant of Restricted Shares to Participants of the 2026 Restricted Share Incentive Plan

Important Content Tips:

1. Initial grant date of restricted shares: July 1, 2026;

2. Number of restricted shares initially granted: 4.00 million shares;

3. Initial grant price of restricted shares: 28.50 yuan/share;

4. Number of initial participants: 223;

5. Equity incentive method: Class II restricted shares.

Hangzhou Baicheng Medical Technology Co., Ltd. (hereinafter referred to as the "Company") held the 13th meeting of the 4th Board of Directors on July 1, 2026, and deliberated and approved the "Proposal on the Initial Grant of Restricted Shares to Participants of the 2026 Restricted Share Incentive Plan." The Board of Directors believes that the grant conditions stipulated in the "2026 Restricted Share Incentive Plan" (hereinafter referred to as the "Incentive Plan") have been met. In accordance with the authorization of the Company's 2026 First Extraordinary General Meeting of Shareholders, it was agreed to set July 1, 2026, as the initial grant date and to grant 4.00 million Class II restricted shares to 223 eligible participants at a grant price of 28.50 yuan/share. The relevant matters are hereby announced as follows:

I. Brief Description of the 2026 Restricted Share Incentive Plan

On June 17, 2026, the Company held the 2026 First Extraordinary General Meeting of Shareholders, which deliberated and approved the "Proposal on the Company's <2026 Restricted Share Incentive Plan (Draft)> and its Summary" and other related proposals. The main contents are as follows:

1. The incentive form adopted by this Incentive Plan is Class II restricted shares. The source of the shares is the Company's A-share common stock issued directly to the participants.

2. This Incentive Plan intends to grant no more than 5.00 million Class II restricted shares to the participants, accounting for approximately 4.58% of the Company's total share capital at the time of the announcement of the draft Incentive Plan. Among them, the initial grant is no more than 4.00 million shares, accounting for approximately 3.66% of the total share capital at the time of the announcement of the draft Incentive Plan, and 80.00% of the total equity to be granted; the reserved grant is no more than 1.00 million shares, accounting for approximately 0.92% of the total share capital at the time of the announcement of the draft Incentive Plan, and 20.00% of the total equity to be granted.

3. The grant price of the restricted shares initially granted to the participants under this Incentive Plan is 28.50 yuan/share. The grant price for the reserved portion of restricted shares is the same as the grant price for the initially granted restricted shares.

4. The participants initially granted under this Incentive Plan include directors, senior management, and core technical (business) personnel of the Company (including subsidiaries) who are in office at the time of the Company's announcement of this Incentive Plan. The participants do not include independent directors, nor do they include shareholders or actual controllers who individually or collectively hold more than 5% of the Company's shares, or their spouses, parents, or children.

The participants intended for the initial grant under this Incentive Plan include one employee of Chinese Macao nationality. This employee serves as the General Manager of Baicheng Medical (Macao) Co., Ltd., is responsible for the Company's business expansion in Macao, and plays an important role in operation and management. Therefore, including this employee in the Incentive Plan is in line with the Company's actual situation and development needs, and is necessary and reasonable.